• CytomX Therapeutics appointed Mamata Gokhale as senior vice president of regulatory affairs to lead global regulatory strategy for its PROBODY pipeline, with a focus on advancing lead program Varseta-M toward potential commercialization.
• Varseta-M is expected to potentially move into a registrational study in late-line colorectal cancer by the first half of 2027.
• Gokhale most recently served as vice president of global regulatory affairs at Perspective Therapeutics, leading regulatory strategy for multiple oncology programs.
• She previously held the same role at Sierra Oncology, where she led regulatory strategy tied to U.S. and European approvals of OJJAARA (momelotinib).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180800PRIMZONEFULLFEED9719337) on May 18, 2026, and is solely responsible for the information contained therein.